Kyowa Kirin

Kyowa Hakko Kirin engages in the manufacture and sale of medical products and pharmaceuticals.

Launch date

1885

Employees

1001-5000 people

Market cap

Enterprise valuation

AUD16.7b (Public information from Sep 2024)

Tokyo Japan (HQ)

http://kyowakirin.co.jp

https://twitter.com/kyowakirin_jp https://www.linkedin.com/company/kyowa-hakko-kirin-co.-ltd.

Revenues, earnings & profits over time

JPY	2020	2021	2022	2023	2024	2025	2026
Revenues	318.4b	352.2b	398.4b	442.2b	488.9b	499.1b	523.4b
% growth	4 %	11 %	13 %	11 %	11 %	2 %	5 %
EBITDA	73.0b	80.7b	87.1b	118.5b	115.5b	122.1b	135.8b
% EBITDA margin	23 %	23 %	22 %	27 %	24 %	24 %	26 %
Profit	47.0b	52.3b	53.6b	81.2b	68.2b	73.9b	81.8b
% profit margin	15 %	15 %	13 %	18 %	14 %	15 %	16 %
EV / revenue	3.9x	3.8x	3.2x	2.0x	2.9x	2.8x	2.6x
EV / EBITDA	16.8x	16.7x	14.7x	7.3x	12.3x	11.3x	9.9x
R&D budget	52.3b	57.7b	62.9b	72.1b	-	-	-
R&D % of revenue	16 %	16 %	16 %	16 %	-	-	-

Date	Investors	Amount	Round
Aug 1949	N/A	N/A	IPO
May 1999	N/A	N/A	IPO
Total Funding		-

Dicerna Pharmaceuticals

ACQUISITION by Novo Nordisk Nov 2021

Orchard Therapeutics

ACQUISITION by Kyowa Kirin Oct 2023

Ring Therapeutics